Drug Profile
ADU 623
Alternative Names: ADU-623Latest Information Update: 18 Aug 2023
Price :
$50
*
At a glance
- Originator Aduro BioTech
- Class Attenuated vaccines; Cancer vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glioblastoma
Most Recent Events
- 11 Aug 2023 Chinook Therapeutics has been acquired by Novartis
- 05 Oct 2020 Aduro Biotech has been merged with Chinook Therapeutics to form Chinook Therapeutics
- 15 Aug 2018 Aduro Biotech in collaboration with Providence Health & Services completes a phase I) trial in Glioblastoma (second-line therapy or greater) in USA (IV) (NCT01967758)